ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
- 1Q20
- On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer
- Announced worldwide license agreement and collaboration with
- 2020 revenue guidance reduced by approximately 5% due to currently anticipated COVID-19 impact
“ACADIA entered 2020 with positive momentum. Successful execution of our commercial efforts led to continued strong performance of NUPLAZID® for Parkinson’s disease psychosis and our plans remain on track for delivering a potential second indication with pimavanserin for the treatment of DRP. We also continue to invest in our late-stage pipeline and business development opportunities to shape our mid and long-term growth strategy,” said
Company Updates
-
ACADIA completed a pre-sNDA meeting with the
U.S. Food and Drug Administration and is on-track to submit a supplemental NDA this summer for pimavanserin as a potential breakthrough therapy for DRP.
- The FDA granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.
-
ACADIA entered into an exclusive worldwide license agreement and research collaboration with
Vanderbilt University , adding an early clinical stage program focused on positive allosteric modulators (PAMs) of the M1 receptor to potentially treat a range of CNS disorders.
Financial Results
Revenue
Net sales of NUPLAZID(pimavanserin) were
Research and Development
Research and development expenses for the three months ended
Selling, General and Administrative
Selling, general and administrative expenses for the three months ended
Net Loss
For the three months ended
Cash and Investments
At
2020 Financial Guidance
ACADIA is revising 2020 net sales and expense guidance to reflect the currently anticipated impact of the COVID-19 pandemic. ACADIA’s 2020 net sales guidance reflects annual revenue growth of approximately 28% for NUPLAZID, at the mid-point of the range.
-
NUPLAZID net sales guidance is decreased to
$420 to$450 million from the previous range of$440 to$470 million . -
GAAP R&D guidance of
$270 to$285 million is unchanged from prior guidance. -
GAAP SG&A guidance is decreased to
$425 to$445 million from the previous range of$440 to$460 million . -
Non-cash stock-based compensation expense guidance of
$90 to$100 million is unchanged compared to prior guidance. -
2020 year-end cash, cash equivalents, and investment securities of
$470 to$500 million is unchanged compared to prior guidance.
Conference Call and Webcast Information
ACADIA management will review its first quarter financial results and operations via conference call and webcast today at
About NUPLAZID® (pimavanserin)
NUPLAZID is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting 5-HT2A receptors that are thought to play an important role in Parkinson’s disease psychosis. NUPLAZID is an oral medicine taken once a day with a recommended dose of 34 mg. NUPLAZID is not FDA-approved for dementia-related psychosis, schizophrenia, major depressive disorder, or depressive symptoms in patients with Parkinson’s disease. ACADIA discovered and developed this new chemical entity and holds worldwide rights to develop and commercialize NUPLAZID.
About Trofinetide
Trofinetide is an investigational drug. It is a novel synthetic analog of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function. In the central nervous system, IGF-1 is produced by both of the major types of brain cells – neurons and glia. IGF-1 in the brain is critical for both normal development and for response to injury and disease. Trofinetide has been granted Fast Track Status and Orphan Drug Designation in the
About
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: the potential opportunity for future growth in sales of NUPLAZID; the timing of ongoing and future clinical studies for pimavanserin; the development and commercialization of trofinetide; unanticipated impacts of COVID-19 on ACADIA’s business, including its commercial sales operations, current and planned clinical trials, supply chain, and guidance for full-year 2020 NUPLAZID net sales and certain expense line items. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the uncertainty of future commercial sales and related items that would impact net sales during 2020, the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended
|
|
|||||||
|
|
Three Months Ended |
||||||
|
|
2020 |
2019 |
|||||
|
Revenues |
|
|
|
|
|||
|
Product sales, net |
$ |
90,068 |
$ |
62,959 |
|
||
|
Total revenues |
|
90,068 |
|
62,959 |
|
||
|
Operating expenses |
|
|
|
|
|||
|
Cost of product sales, license fees and royalties (1) |
|
4,974 |
|
4,580 |
|
||
|
Research and development (1) |
|
72,636 |
|
52,923 |
|
||
|
Selling, general and administrative (1) |
|
101,973 |
|
93,090 |
|
||
|
Total operating expenses |
|
179,583 |
|
150,593 |
|
||
|
Loss from operations |
(89,515 |
) |
(87,634 |
) | |||
|
Interest income, net |
|
2,989 |
|
2,934 |
|
||
|
Other expense |
(1,497 |
) |
(229 |
) |
|||
|
Loss before income taxes |
|
(88,023 |
) |
|
(84,929 |
) |
|
|
Income tax expense |
|
— |
|
375 |
|
||
|
Net loss |
$ |
(88,023 |
) |
$ |
(85,304 |
) |
|
|
Net loss per common share, basic and diluted |
$ |
(0.57 |
) |
$ |
(0.59 |
) |
|
|
Weighted average common shares outstanding, basic and diluted |
|
155,368 |
|
143,981 |
|
||
|
|
|
|
|
|
|||
|
|
|
|
|
|
|||
|
(1) Includes the following stock-based compensation expense |
|
|
|
|
|||
|
|
|
|
|
|
|||
|
Cost of product sales, license fees and royalties |
$ |
849 |
$ |
995 |
|
||
|
Research and development |
$ |
8,457 |
$ |
7,880 |
|
||
|
Selling, general and administrative |
$ |
13,042 |
$ |
11,008 |
|
||
|
|
||||||||||
|
|
|
|
|
|
|
|
||||
|
|
|
(unaudited) |
|
|
|
|
|
|||
|
Assets |
|
|
|
|
|
|
|
|
||
|
Cash, cash equivalents and investment securities |
|
$ |
|
651,406 |
|
|
$ |
|
697,429 |
|
|
Accounts receivable, net |
|
|
41,636 |
|
|
|
35,781 |
|
||
|
Interest and other receivables |
|
|
2,935 |
|
|
|
2,093 |
|
||
|
Inventory |
|
|
6,318 |
|
|
|
6,341 |
|
||
|
Prepaid expenses |
|
|
22,126 |
|
|
|
18,606 |
|
||
|
Total current assets |
|
|
724,421 |
|
|
|
760,250 |
|
||
|
Property and equipment, net |
|
|
5,089 |
|
|
|
3,180 |
|
||
|
Operating lease right-of-use assets |
|
|
8,613 |
|
|
|
9,524 |
|
||
|
Intangible assets, net |
|
|
2,215 |
|
|
|
2,585 |
|
||
|
Restricted cash |
|
|
5,770 |
|
|
|
4,787 |
|
||
|
Other assets |
|
|
1,342 |
|
|
|
2,857 |
|
||
|
Total assets |
|
$ |
|
747,450 |
|
|
$ |
|
783,183 |
|
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
|
6,623 |
|
|
$ |
|
7,222 |
|
|
Accrued liabilities |
|
|
93,118 |
|
|
|
67,604 |
|
||
|
Total current liabilities |
|
|
99,741 |
|
|
|
74,826 |
|
||
|
Operating lease liabilities |
|
|
6,090 |
|
|
|
6,361 |
|
||
|
Other long-term liabilities |
|
|
3,237 |
|
|
|
2,861 |
|
||
|
Total liabilities |
|
|
109,068 |
|
|
|
84,048 |
|
||
|
Total stockholders’ equity |
|
|
638,382 |
|
|
|
699,135 |
|
||
|
Total liabilities and stockholders’ equity |
|
$ |
|
747,450 |
|
|
$ |
|
783,183 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200507005977/en/
Media Contact:
(858) 212-0534
media@acadia-pharm.com
Investor Contact:
(858) 261-2771
ir@acadia-pharm.com
Source: